Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial.
Katya C CoradoKara W ChewMark J GigantiYing MuCourtney V FletcherJudith S CurrierEric S DaarDavid A WohlJonathan Z LiCarlee B MoserJustin RitzArzhang Cyrus JavanGene NeytmanMarina CaskeyMichael D HughesDavey M SmithJoseph J Eronnull nullPublished in: Pathogens & immunity (2024)
While safe, the BMS mAbs delivered subcutaneously were not effective at treating COVID-19 at low risk for progression. The lack of clinically significant activity may relate to the pharmacokinetics of subcutaneous administration of mAbs.